View ValuationHarvard Apparatus Regenerative Technology 将来の成長Future 基準チェック /06現在、 Harvard Apparatus Regenerative Technologyの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 29Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant At Mayo ClinicHarvard Apparatus Regenerative Technology Inc. announced that the first patient has been treated with its Cellspan Esophageal Implant (CEI) in the Company’s Phase 1 feasibility and safety clinical trial conducted at the Mayo Clinic in Rochester, Minnesota. Life-Threatening esophageal disease, including severe strictures, represents a significant unmet medical need. Current treatment options are limited and often involve highly invasive procedures with substantial morbidity. The Cellspan Esophageal Implant is designed to leverage the patient’s own regenerative capacity, offering a potential alternative to conventional surgical reconstruction. The Company’s Phase 1 clinical trial is a feasibility and safety study in up to ten patients under an FDA-approved IND. We activated three clinical trial sites, the Mayo Clinic, the University of Michigan Medical Center and the University of Southern California in Los Angeles. The primary endpoint of the ongoing trial is the establishment of a continuous biological neoconduit, or tube, by three months post-surgery. One of the secondary endpoints will be the development of a mucosal lining in the esophagus by twelve months post-surgery. CellSpan Esophageal Implant (CEI) is a combination product. It consists of a modified polyurethane tubular CellFrame mesh scaffold with direct delivery of live autologous adipose derived Mesenchymal Stromal Cells to the esophagus. The CEI provides temporary support during the initial tissue growth phase, and the scaffold is removed endoscopically at 21–42 days post implant. The Company extends its sincere appreciation to IQVIA Biotech for their exceptional project management, site activation support, and cross-functional coordination throughout this Phase 1 clinical trial. From study start-up through first patient treatment, IQVIA Biotech's dedicated team ensured seamless site readiness, protocol adherence, and operational execution, playing an integral role in bringing this clinical milestone to completion on time and to the highest standards of quality. Harvard Apparatus Regenerative Technology also extends its deepest appreciation to the entire clinical and research team at the Mayo Clinic for their professionalism, dedication, and collaborative spirit in bringing this milestone to fruition. The Company looks forward to continuing this important partnership as the program advances. We conducted the world’s first successful regeneration of the esophagus in a patient with esophageal cancer in August 2017. This surgery was performed by Dr. Dennis Wigle, Chair of Thoracic Surgery at the Mayo Clinic. The results were published in the Journal of Thoracic Oncology Clinical and Research Reports in August 2021. HRGN has 13 issued U.S. patents, 2 issued in China, 1 issued in Japan, 2 issued in Europe, 2 U.S. orphan-drug designations which can provide seven years of market exclusivity in the US market after market approval from the FDA and 1 EMA orphan drug designation, which can provide ten years of market exclusivity in the European market after market approval from the EMA.お知らせ • Apr 24Harvard Apparatus Regenerative Technology Inc., Annual General Meeting, Jun 18, 2026Harvard Apparatus Regenerative Technology Inc., Annual General Meeting, Jun 18, 2026. Location: at 84 october hill road, suite 11, ma 01746., holliston United Statesお知らせ • Apr 18Harvard Apparatus Regenerative Technology Inc., Annual General Meeting, Jun 20, 2025Harvard Apparatus Regenerative Technology Inc., Annual General Meeting, Jun 20, 2025. Location: 84 october hill road, suite 11, holliston, ma 01746., United Statesお知らせ • Aug 27+ 1 more updateHarvard Apparatus Regenerative Technology Inc. Appoints Mao Zhang to Board of DirectorsHarvard Apparatus Regenerative Technology Inc. announced the appointment of Mao Zhang as an independent director to its Board of Directors, adding strength in the areas of business innovation, strategy and finance. Mr. Mao Zhang is the Founder and Chief Executive Officer of StellarS Capital, a multi-billion-dollar alternative asset management firm established in 2016. He has over 15 years of experience in financial markets including hedge fund and private equity. He began his career with Magnetar Capital in 2007, leading its Asian business. He holds a Bachelor of Science degree from the University of Pennsylvania. Mao's deep business and investment experience will be instrumental in helping the company to pursue the mission to serve the unmet patient needs. His appointment will be invaluable to Harvard Apparatus Regenerative Technology at a time of significant opportunity and growth.お知らせ • Aug 07Harvard Apparatus Regenerative Technology Inc. announced that it has received $1.482101 million in fundingOn August 6, 2024, Harvard Apparatus Regenerative Technology Inc. closed the transaction.お知らせ • May 01Harvard Apparatus Regenerative Technology Inc., Annual General Meeting, Jun 20, 2024Harvard Apparatus Regenerative Technology Inc., Annual General Meeting, Jun 20, 2024, at 09:30 Eastern Daylight. Location: 84 October Hill Road, Suite 11, 01746 Holliston Massachusetts United States Agenda: To elect three Director nominees as Class II Directors, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2027 and until such Director’s successor is duly elected and qualified, or until his resignation or removal; to ratify the appointment of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; to consider and vote, on a non-binding advisory basis, as to the approval of the compensation of named executive officers as disclosed in this proxy statement; and to consider and vote upon such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.お知らせ • Nov 10Harvard Apparatus Regenerative Technology Inc. to Report Q3, 2023 Results on Nov 13, 2023Harvard Apparatus Regenerative Technology Inc. announced that they will report Q3, 2023 results on Nov 13, 2023お知らせ • Aug 10Harvard Apparatus Regenerative Technology Inc. to Report Q2, 2023 Results on Aug 14, 2023Harvard Apparatus Regenerative Technology Inc. announced that they will report Q2, 2023 results on Aug 14, 2023お知らせ • Jul 21Biostage, Inc. Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal DiseaseBiostage, Inc. announced that it officially activated the site with Mayo Clinic for its clinical trial as to severe esophageal disease, being its first clinical trial in the United States. The Phase 1, first-in-human study approved by the FDA will evaluate both safety and efficacy in up to ten patients requiring the removal of up to 6 cm of their esophagus (including cancer, trauma or birth defects) at up to five hospitals in the U.S. The primary endpoint is the development of a continuous biological neo-conduit at three months following implantation.お知らせ • Jun 06Biostage, Inc., Annual General Meeting, Jul 19, 2023Biostage, Inc., Annual General Meeting, Jul 19, 2023, at 09:30 Eastern Daylight. Location: 84 October Hill Road, Suite 11 Holliston Massachusetts United States Agenda: To consider election of directors; to ratify the appointment of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023; to approve an amendment to Amended and Restated Equity Incentive Plan to increase the number of shares of common stock available for issuance pursuant thereto; to consider and vote, on a non-binding advisory basis, as to the approval of the compensation of named executive officers as disclosed in the proxy statement; and to consider and vote upon such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.お知らせ • Jun 01+ 1 more updateBiostage, Inc. Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal DiseaseBiostage, Inc. announced that it initiated start-up activities for its first clinical trial. The Phase 1, first-in-human study approved by the FDA will evaluate both safety and efficacy in up to ten patients requiring the removal of up to 6 cm of their esophagus (including cancer, trauma or birth defects) at up to five hospitals in the U.S. The primary endpoint is the development of a continuous biological neo-conduit at three months following implantation.お知らせ • Jan 13Biostage, Inc. Amends CEO Employment AgreementBiostage, Inc. announced that effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interim designation from his Chief Executive Officer title effective immediately, and also amend certain terms of Mr. Green's existing Employment Agreement.お知らせ • Dec 24Biostage, Inc. Announces New Publication Demonstrates Rapid Esophageal Regeneration Using the Biostage Esophageal ImplantBiostage, Inc. announced the publication of a paper in the peer-reviewed Journal of Immunology and Regenerative Medicine that describes the early tissue growth and regeneration processes following the implantation of the Biostage Esophageal Implant (BEI) in nine pigs with full circumferential esophageal segmental replacement. The BEI stimulated new blood vessel growth and all animals regenerated a continuous biological conduit by 28 days. The regeneration time period as noted in the paper compares favorably with the primary endpoint of Biostage's FDA-approved clinical trial which is to show a continuous biological conduit by 90 days. Biostage expects to initiate patient recruitment in its first clinical trial in early 2023. The Biostage Esophageal Implant (previously known as Cellspan Esophageal Implant) stimulates the regeneration of new tissue to repair the esophagus following a full circumferential segmental resection. The paper in the Journal of Immunology and Regenerative Medicine describes a study that investigated the early growth and tissue composition of the newly developed tissue as well as the fate of the adipose derived mesenchymal stromal cells (Ad-MSC) that are seeded onto the scaffold prior to implantation. The BEI bridged the esophageal ends and restored the conduit by stimulating a regeneration process that includes rapid neovascularization followed by mucosal regeneration that was quantified from day 14 to day 28 post-implantation.お知らせ • Nov 11Biostage, Inc. to Report Q3, 2022 Results on Nov 14, 2022Biostage, Inc. announced that they will report Q3, 2022 results on Nov 14, 2022お知らせ • Aug 09Biostage, Inc. Announces Appointment of Joseph Damasio as New Chief Financial OfficerBiostage, Inc. announced the appointment of Joseph Damasio as the company's new Chief Financial Officer. Joe provides Biostage with considerable experience in raising capital and running operations for small-cap biotech companies. Recently his experience has included CFO, VP Finance and Controller roles at: Inhibikase Therapeutics, Cue Biopharma and Pressure Biosciences. He has managed multiple capital raises, both private and public, including uplisting to NASDAQ. Joe holds a BS in Accounting from the University of Massachusetts (Dartmouth), an MS in Finance from Boston College and an MBA from Boston College. He is a Massachusetts-licensed CPA, a former auditor with PriceWaterhouseCoopers and formerly served in the U.S. Navy.お知らせ • Aug 05Biostage, Inc. to Report Q2, 2022 Results on Aug 04, 2022Biostage, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 04, 2022お知らせ • Jun 16Biostage, Inc. Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of BiomechanicsBiostage, Inc. announced the publication of a paper in the peer-reviewed Journal of Biomechanics, describing a study investigating the mechanical strength of regenerated esophageal tissues. The Biostage Esophageal Implant (previously known as Cellspan Esophageal Implant) stimulates the regeneration of new tissue to repair the esophagus following segmental resection of the thoracic esophagus. Using a porcine model, the paper in the Journal of Biomechanics describes a study that tested the mechanical strength of the newly developed tissue as well as the flanking native tissue using a probe-burst pressure test on explanted tissues at three time points post-implantation. The BEI bridged the proximal and distal native esophageal ends to restore the conduit by stimulating a regeneration process that progressed from a fibrovascular scar at 30-days to a fully epithelialized lumen at 90-days, followed by submucosal regeneration and regeneration of a 'laminated' adventitia with smooth muscle development in the 365-day cohort. The burst strength of the regenerated tissues at all three time points were comparable to the native tissue flanking the implant and the overall pressure required to burst through the tissue increased with increasing time post-surgery.お知らせ • May 18Biostage, Inc. announced that it has received $5.060244 million in fundingOn May 16, 2022, Biostage, Inc. closed the transaction. The company issued 43,960 units for gross proceeds of $260,000 in its second and final tranche bringing the total gross proceeds raised in the transaction to $5,060,244.32.お知らせ • May 14Biostage, Inc. Announces $5.1 Million Financing to Advance Clinical TrialBiostage, Inc. announced that it has raised approximately $5.1 million from new and existing investors in a private placement of its shares. Additional details are provided below. The funds will be used to accelerate the clinical development of Biostage's lead product candidate, the Biostage Esophageal Implant, or BEI. The FDA has approved a ten-patient phase one and phase two clinical trial to study the repair of damage to the esophagus in adults caused by cancer or injury. The FDA has indicated a willingness to consider expanding this clinical trial to include pediatric subjects with birth defects in the esophagus once the safety of the implant is shown in adults. Hence, the Company expects the repair of birth defects in the esophagus to be an additional indication for which Biostage will seek FDA approval. Biostage is also developing other uses of its technology such as for treating cancer of the lung using the Biostage Bronchial Implant. Similar to how the BEI could be used to regenerate the esophagus, the Biostage Bronchial Implant would be used to regenerate a bronchus that has been surgically removed to treat bronchial cancer, injury or birth defects.お知らせ • May 12Biostage, Inc. to Report Q1, 2022 Results on May 16, 2022Biostage, Inc. announced that they will report Q1, 2022 results on May 16, 2022お知らせ • May 03Biostage, Inc., Annual General Meeting, Jun 22, 2022Biostage, Inc., Annual General Meeting, Jun 22, 2022, at 08:00 Eastern Daylight. Agenda: To elect two Director nominees as Class III Directors, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2025 and until such Director’s successor is duly elected and qualified or until her earlier resignation or removal; to consider and vote, on a non-binding advisory basis, as to the approval of the compensation of the company's named executive officers; to consider and vote, on a non-binding advisory basis, as to the frequency of future advisory votes on the compensation of the company's named executive officers; and to consider and vote upon such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.お知らせ • Jan 26Biostage Announces Court's Preliminary Injunction Order Requiring Its Insurance Carrier to Continue Paying for DefenseBiostage, Inc. announced that a Court has ordered that its medical liability insurance carrier, Medmarc, breached its duty to defend the Company when Medmarc unilaterally stopped paying Biostage's legal bills for the defense in the litigation from the estate of a patient who died after being treated with a Biostage Tracheal Implant. In September 2021, Medmarc filed a lawsuit seeking to be relieved of its duty to defend and indemnify Biostage in the litigation. At that time, Medmarc stopped paying the Company's defense costs in the litigation. Biostage responded by filing claims against Medmarc for insurance coverage, and Biostage also brought a motion seeking the Court to Order Medmarc to continue paying for the Company's reasonable defense costs in the underlying litigation while the coverage dispute is pending. The Court granted Biostage's motion for preliminary injunction and held that Medmarc breached its duty to defend the Company when it unilaterally stopped paying for the defense. The Court expressly stated that Medmarc engaged in "unlawful conduct" by unilaterally terminating the defense. Although the coverage dispute remains pending between the parties, the Court held that "Medmarc will mostly likely lose its claim" seeking to terminate the payment of the defense, and therefore, it must continue to pay the defense until the coverage dispute is resolved. The Court also awarded Biostage its attorneys' fees and costs arising from Medmarc's breach of the duty to defend. The Court's decision states that "when an insured goes to court and shows that the insurer has breached its duty to defend, the insured is entitled to recovery any reasonable attorneys' fees and other litigation expenses that it incurred to do so." Biostage has since discontinued development of the Biostage Tracheal Implant and is now pursuing the development of the Biostage Esophageal Implant to treat adults with severe esophageal disease (including esophageal cancer), and also birth defects in the esophagus in babies.お知らせ • Jan 12Biostage Announces Publication of Paper Establishing the Basis for Using its Product to Treat Birth Defects in the Esophagus in BabiesBiostage, Inc. announced the publication of paper establishing the basis for using its product to treat birth defects in the esophagus in babies. The piglets gained weight steadily over the course of the study and eventually tripled their size, showing that the regenerated esophagus grows with the patient. The paper states that current techniques for repairing birth defects in the esophagus, "have significant costs, complication rates, lengthy hospital stays, and significant morbidities. Therefore, the development of novel approaches that bridge a primary long gap…are highly desired." Dr. Christine Finck, Surgeon in Chief, Connecticut Children's Medical Center, who performed the surgeries, said "this technology has the potential to provide a novel therapy for some of their must fragile patients." Biostage has previously reported on the first-in-human regeneration of an esophagus in an adult cancer patient, performed at Mayo Clinic and published in JTO Clinical and Research Reports in August 2021. That paper concluded that the Biostage Esophageal Implant would have, "considerable clinical use." The FDA has already approved a 10-patient, phase 1/2 clinical trial for repair of the esophagus in adults. The FDA has indicated a willingness to consider expanding the current clinical trial to include pediatric subjects once the safety of the implant is shown in adults. Hence, they expect the repair of birth defects in the esophagus to be an additional indication for which Biostage will seek FDA approval.お知らせ • May 18Biostage, Inc. announced delayed 10-Q filingOn 05/17/2021, Biostage, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Biostage, Inc. announced delayed annual 10-K filingOn 03/31/2021, Biostage, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 05Biostage, Inc. Announces Resignation of James Mastridge as Interim Vice President of Finance or Principal Accounting and Financial OfficerOn January 29, 2021, Danforth Advisors, LLC (“Danforth”) notified Biostage, Inc. (the “Company”), that Danforth was terminating its Consulting Agreement with the Company. As a result and effective as of such termination, James Mastridge, is no longer serving as the Company’s interim Vice President of Finance or principal accounting and financial officer. The Company is actively in the process of identifying a qualified candidate to serve as the Company’s principal accounting and financial officer.お知らせ • Jan 26Biostage, Inc. Appoints Herman Sanchez as an Independent DirectorBiostage, Inc. announced that it appointed Herman Sanchez as an independent director to its Board of Directors. Mr. Sanchez has been working in the life sciences industry for over 20 years in various positions including designing and running randomized trial research, optimizing of clinical administration of health services, and working as a strategic consultant to the life sciences industry. He is currently a Senior Partner helping run Trinity Life Sciences’ strategy consulting business. He joined Trinity over a decade ago and has worked closely with clients to support strategic decision making across the product lifecycle. In his work consulting for pharmaceutical/biotech and medical device companies he has covered several diseases/therapeutic areas including oncology, rare and ultra-rare diseases, cell therapies, cardiovascular, diabetes, alcohol abuse/dependence, neurological, orthopedic, and renal diseases. He has been published in peer-reviewed publications on various topics including renal disease, patient epidemiology, medication adherence, suicidal ideation, minority patient recruiting, alcohol use/abuse and depression/anxiety treatment. Mr. Sanchez, prior to working in the life sciences industry, earned an MBA from the Tuck School of Business at Dartmouth and an AB in Psychology from Harvard University.お知らせ • Aug 21+ 1 more updateBiostage, Inc. announced that it expects to receive $0.3 million in funding from Dao Capital Group LimitedBiostage, Inc. (OTCPK:BSTG) announced that entered into securities purchase agreement for a private placement of 75,000 common shares at a price if $4 per share for gross proceeds of $300,000 on August 18, 2020. The transaction included participation from Dao Capital Group Limited. No brokerage or finder’s fees or commissions are or will be payable by the company. The securities will be issued pursuant to exemption provided under Regulation D. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Harvard Apparatus Regenerative Technology は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:HRGN - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261-7-4-4N/A12/31/20251-7-4-4N/A9/30/20251-7-4-4N/A6/30/20251-7-4-4N/A3/31/20250-7-5-5N/A12/31/20240-8-5-5N/A9/30/20240-8-5-5N/A6/30/20240-8-7-7N/A3/31/20240-8-7-7N/A12/31/20230-9-7-7N/A9/30/20230-9-7-7N/A6/30/2023N/A-8-6-6N/A3/31/2023N/A-7-6-6N/A12/31/2022N/A-6-5-5N/A9/30/2022N/A-11-4-4N/A6/30/2022N/A-10-3-3N/A3/31/2022N/A-9-3-3N/A12/31/2021N/A-8-3-3N/A9/30/2021N/A-3-3-3N/A6/30/2021N/A-3-3-3N/A3/31/2021N/A-4-4-4N/A12/31/2020N/A-5-4-4N/A9/30/2020N/A-5-4-4N/A6/30/2020N/A-7-5-5N/A3/31/2020N/A-8-6-6N/A12/31/2019N/A-8N/A-6N/A9/30/2019N/A-9N/A-7N/A6/30/2019N/A-8N/A-8N/A3/31/2019N/A-8N/A-7N/A12/31/2018N/A-8N/A-8N/A9/30/2018N/A-7N/A-7N/A6/30/2018N/A-8N/A-8N/A3/31/2018N/A-10N/A-10N/A12/31/2017N/A-12N/A-11N/A9/30/20170-14N/A-12N/A6/30/20170-14N/A-11N/A3/31/20170-13N/A-10N/A12/31/20160-12N/A-9N/A9/30/20160-11N/A-8N/A6/30/20160-10N/A-7N/A3/31/20160-12N/A-8N/A12/31/20150-12N/A-7N/A9/30/20150-12N/A-8N/A6/30/20150-13N/A-8N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: HRGNの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: HRGNの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: HRGNの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: HRGNの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: HRGNの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: HRGNの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 13:31終値2026/05/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Harvard Apparatus Regenerative Technology Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Jason KolbertMaxim GroupPamela BassettMaxim Group
お知らせ • Apr 29Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant At Mayo ClinicHarvard Apparatus Regenerative Technology Inc. announced that the first patient has been treated with its Cellspan Esophageal Implant (CEI) in the Company’s Phase 1 feasibility and safety clinical trial conducted at the Mayo Clinic in Rochester, Minnesota. Life-Threatening esophageal disease, including severe strictures, represents a significant unmet medical need. Current treatment options are limited and often involve highly invasive procedures with substantial morbidity. The Cellspan Esophageal Implant is designed to leverage the patient’s own regenerative capacity, offering a potential alternative to conventional surgical reconstruction. The Company’s Phase 1 clinical trial is a feasibility and safety study in up to ten patients under an FDA-approved IND. We activated three clinical trial sites, the Mayo Clinic, the University of Michigan Medical Center and the University of Southern California in Los Angeles. The primary endpoint of the ongoing trial is the establishment of a continuous biological neoconduit, or tube, by three months post-surgery. One of the secondary endpoints will be the development of a mucosal lining in the esophagus by twelve months post-surgery. CellSpan Esophageal Implant (CEI) is a combination product. It consists of a modified polyurethane tubular CellFrame mesh scaffold with direct delivery of live autologous adipose derived Mesenchymal Stromal Cells to the esophagus. The CEI provides temporary support during the initial tissue growth phase, and the scaffold is removed endoscopically at 21–42 days post implant. The Company extends its sincere appreciation to IQVIA Biotech for their exceptional project management, site activation support, and cross-functional coordination throughout this Phase 1 clinical trial. From study start-up through first patient treatment, IQVIA Biotech's dedicated team ensured seamless site readiness, protocol adherence, and operational execution, playing an integral role in bringing this clinical milestone to completion on time and to the highest standards of quality. Harvard Apparatus Regenerative Technology also extends its deepest appreciation to the entire clinical and research team at the Mayo Clinic for their professionalism, dedication, and collaborative spirit in bringing this milestone to fruition. The Company looks forward to continuing this important partnership as the program advances. We conducted the world’s first successful regeneration of the esophagus in a patient with esophageal cancer in August 2017. This surgery was performed by Dr. Dennis Wigle, Chair of Thoracic Surgery at the Mayo Clinic. The results were published in the Journal of Thoracic Oncology Clinical and Research Reports in August 2021. HRGN has 13 issued U.S. patents, 2 issued in China, 1 issued in Japan, 2 issued in Europe, 2 U.S. orphan-drug designations which can provide seven years of market exclusivity in the US market after market approval from the FDA and 1 EMA orphan drug designation, which can provide ten years of market exclusivity in the European market after market approval from the EMA.
お知らせ • Apr 24Harvard Apparatus Regenerative Technology Inc., Annual General Meeting, Jun 18, 2026Harvard Apparatus Regenerative Technology Inc., Annual General Meeting, Jun 18, 2026. Location: at 84 october hill road, suite 11, ma 01746., holliston United States
お知らせ • Apr 18Harvard Apparatus Regenerative Technology Inc., Annual General Meeting, Jun 20, 2025Harvard Apparatus Regenerative Technology Inc., Annual General Meeting, Jun 20, 2025. Location: 84 october hill road, suite 11, holliston, ma 01746., United States
お知らせ • Aug 27+ 1 more updateHarvard Apparatus Regenerative Technology Inc. Appoints Mao Zhang to Board of DirectorsHarvard Apparatus Regenerative Technology Inc. announced the appointment of Mao Zhang as an independent director to its Board of Directors, adding strength in the areas of business innovation, strategy and finance. Mr. Mao Zhang is the Founder and Chief Executive Officer of StellarS Capital, a multi-billion-dollar alternative asset management firm established in 2016. He has over 15 years of experience in financial markets including hedge fund and private equity. He began his career with Magnetar Capital in 2007, leading its Asian business. He holds a Bachelor of Science degree from the University of Pennsylvania. Mao's deep business and investment experience will be instrumental in helping the company to pursue the mission to serve the unmet patient needs. His appointment will be invaluable to Harvard Apparatus Regenerative Technology at a time of significant opportunity and growth.
お知らせ • Aug 07Harvard Apparatus Regenerative Technology Inc. announced that it has received $1.482101 million in fundingOn August 6, 2024, Harvard Apparatus Regenerative Technology Inc. closed the transaction.
お知らせ • May 01Harvard Apparatus Regenerative Technology Inc., Annual General Meeting, Jun 20, 2024Harvard Apparatus Regenerative Technology Inc., Annual General Meeting, Jun 20, 2024, at 09:30 Eastern Daylight. Location: 84 October Hill Road, Suite 11, 01746 Holliston Massachusetts United States Agenda: To elect three Director nominees as Class II Directors, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2027 and until such Director’s successor is duly elected and qualified, or until his resignation or removal; to ratify the appointment of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; to consider and vote, on a non-binding advisory basis, as to the approval of the compensation of named executive officers as disclosed in this proxy statement; and to consider and vote upon such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
お知らせ • Nov 10Harvard Apparatus Regenerative Technology Inc. to Report Q3, 2023 Results on Nov 13, 2023Harvard Apparatus Regenerative Technology Inc. announced that they will report Q3, 2023 results on Nov 13, 2023
お知らせ • Aug 10Harvard Apparatus Regenerative Technology Inc. to Report Q2, 2023 Results on Aug 14, 2023Harvard Apparatus Regenerative Technology Inc. announced that they will report Q2, 2023 results on Aug 14, 2023
お知らせ • Jul 21Biostage, Inc. Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal DiseaseBiostage, Inc. announced that it officially activated the site with Mayo Clinic for its clinical trial as to severe esophageal disease, being its first clinical trial in the United States. The Phase 1, first-in-human study approved by the FDA will evaluate both safety and efficacy in up to ten patients requiring the removal of up to 6 cm of their esophagus (including cancer, trauma or birth defects) at up to five hospitals in the U.S. The primary endpoint is the development of a continuous biological neo-conduit at three months following implantation.
お知らせ • Jun 06Biostage, Inc., Annual General Meeting, Jul 19, 2023Biostage, Inc., Annual General Meeting, Jul 19, 2023, at 09:30 Eastern Daylight. Location: 84 October Hill Road, Suite 11 Holliston Massachusetts United States Agenda: To consider election of directors; to ratify the appointment of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023; to approve an amendment to Amended and Restated Equity Incentive Plan to increase the number of shares of common stock available for issuance pursuant thereto; to consider and vote, on a non-binding advisory basis, as to the approval of the compensation of named executive officers as disclosed in the proxy statement; and to consider and vote upon such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
お知らせ • Jun 01+ 1 more updateBiostage, Inc. Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal DiseaseBiostage, Inc. announced that it initiated start-up activities for its first clinical trial. The Phase 1, first-in-human study approved by the FDA will evaluate both safety and efficacy in up to ten patients requiring the removal of up to 6 cm of their esophagus (including cancer, trauma or birth defects) at up to five hospitals in the U.S. The primary endpoint is the development of a continuous biological neo-conduit at three months following implantation.
お知らせ • Jan 13Biostage, Inc. Amends CEO Employment AgreementBiostage, Inc. announced that effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interim designation from his Chief Executive Officer title effective immediately, and also amend certain terms of Mr. Green's existing Employment Agreement.
お知らせ • Dec 24Biostage, Inc. Announces New Publication Demonstrates Rapid Esophageal Regeneration Using the Biostage Esophageal ImplantBiostage, Inc. announced the publication of a paper in the peer-reviewed Journal of Immunology and Regenerative Medicine that describes the early tissue growth and regeneration processes following the implantation of the Biostage Esophageal Implant (BEI) in nine pigs with full circumferential esophageal segmental replacement. The BEI stimulated new blood vessel growth and all animals regenerated a continuous biological conduit by 28 days. The regeneration time period as noted in the paper compares favorably with the primary endpoint of Biostage's FDA-approved clinical trial which is to show a continuous biological conduit by 90 days. Biostage expects to initiate patient recruitment in its first clinical trial in early 2023. The Biostage Esophageal Implant (previously known as Cellspan Esophageal Implant) stimulates the regeneration of new tissue to repair the esophagus following a full circumferential segmental resection. The paper in the Journal of Immunology and Regenerative Medicine describes a study that investigated the early growth and tissue composition of the newly developed tissue as well as the fate of the adipose derived mesenchymal stromal cells (Ad-MSC) that are seeded onto the scaffold prior to implantation. The BEI bridged the esophageal ends and restored the conduit by stimulating a regeneration process that includes rapid neovascularization followed by mucosal regeneration that was quantified from day 14 to day 28 post-implantation.
お知らせ • Nov 11Biostage, Inc. to Report Q3, 2022 Results on Nov 14, 2022Biostage, Inc. announced that they will report Q3, 2022 results on Nov 14, 2022
お知らせ • Aug 09Biostage, Inc. Announces Appointment of Joseph Damasio as New Chief Financial OfficerBiostage, Inc. announced the appointment of Joseph Damasio as the company's new Chief Financial Officer. Joe provides Biostage with considerable experience in raising capital and running operations for small-cap biotech companies. Recently his experience has included CFO, VP Finance and Controller roles at: Inhibikase Therapeutics, Cue Biopharma and Pressure Biosciences. He has managed multiple capital raises, both private and public, including uplisting to NASDAQ. Joe holds a BS in Accounting from the University of Massachusetts (Dartmouth), an MS in Finance from Boston College and an MBA from Boston College. He is a Massachusetts-licensed CPA, a former auditor with PriceWaterhouseCoopers and formerly served in the U.S. Navy.
お知らせ • Aug 05Biostage, Inc. to Report Q2, 2022 Results on Aug 04, 2022Biostage, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 04, 2022
お知らせ • Jun 16Biostage, Inc. Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of BiomechanicsBiostage, Inc. announced the publication of a paper in the peer-reviewed Journal of Biomechanics, describing a study investigating the mechanical strength of regenerated esophageal tissues. The Biostage Esophageal Implant (previously known as Cellspan Esophageal Implant) stimulates the regeneration of new tissue to repair the esophagus following segmental resection of the thoracic esophagus. Using a porcine model, the paper in the Journal of Biomechanics describes a study that tested the mechanical strength of the newly developed tissue as well as the flanking native tissue using a probe-burst pressure test on explanted tissues at three time points post-implantation. The BEI bridged the proximal and distal native esophageal ends to restore the conduit by stimulating a regeneration process that progressed from a fibrovascular scar at 30-days to a fully epithelialized lumen at 90-days, followed by submucosal regeneration and regeneration of a 'laminated' adventitia with smooth muscle development in the 365-day cohort. The burst strength of the regenerated tissues at all three time points were comparable to the native tissue flanking the implant and the overall pressure required to burst through the tissue increased with increasing time post-surgery.
お知らせ • May 18Biostage, Inc. announced that it has received $5.060244 million in fundingOn May 16, 2022, Biostage, Inc. closed the transaction. The company issued 43,960 units for gross proceeds of $260,000 in its second and final tranche bringing the total gross proceeds raised in the transaction to $5,060,244.32.
お知らせ • May 14Biostage, Inc. Announces $5.1 Million Financing to Advance Clinical TrialBiostage, Inc. announced that it has raised approximately $5.1 million from new and existing investors in a private placement of its shares. Additional details are provided below. The funds will be used to accelerate the clinical development of Biostage's lead product candidate, the Biostage Esophageal Implant, or BEI. The FDA has approved a ten-patient phase one and phase two clinical trial to study the repair of damage to the esophagus in adults caused by cancer or injury. The FDA has indicated a willingness to consider expanding this clinical trial to include pediatric subjects with birth defects in the esophagus once the safety of the implant is shown in adults. Hence, the Company expects the repair of birth defects in the esophagus to be an additional indication for which Biostage will seek FDA approval. Biostage is also developing other uses of its technology such as for treating cancer of the lung using the Biostage Bronchial Implant. Similar to how the BEI could be used to regenerate the esophagus, the Biostage Bronchial Implant would be used to regenerate a bronchus that has been surgically removed to treat bronchial cancer, injury or birth defects.
お知らせ • May 12Biostage, Inc. to Report Q1, 2022 Results on May 16, 2022Biostage, Inc. announced that they will report Q1, 2022 results on May 16, 2022
お知らせ • May 03Biostage, Inc., Annual General Meeting, Jun 22, 2022Biostage, Inc., Annual General Meeting, Jun 22, 2022, at 08:00 Eastern Daylight. Agenda: To elect two Director nominees as Class III Directors, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2025 and until such Director’s successor is duly elected and qualified or until her earlier resignation or removal; to consider and vote, on a non-binding advisory basis, as to the approval of the compensation of the company's named executive officers; to consider and vote, on a non-binding advisory basis, as to the frequency of future advisory votes on the compensation of the company's named executive officers; and to consider and vote upon such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
お知らせ • Jan 26Biostage Announces Court's Preliminary Injunction Order Requiring Its Insurance Carrier to Continue Paying for DefenseBiostage, Inc. announced that a Court has ordered that its medical liability insurance carrier, Medmarc, breached its duty to defend the Company when Medmarc unilaterally stopped paying Biostage's legal bills for the defense in the litigation from the estate of a patient who died after being treated with a Biostage Tracheal Implant. In September 2021, Medmarc filed a lawsuit seeking to be relieved of its duty to defend and indemnify Biostage in the litigation. At that time, Medmarc stopped paying the Company's defense costs in the litigation. Biostage responded by filing claims against Medmarc for insurance coverage, and Biostage also brought a motion seeking the Court to Order Medmarc to continue paying for the Company's reasonable defense costs in the underlying litigation while the coverage dispute is pending. The Court granted Biostage's motion for preliminary injunction and held that Medmarc breached its duty to defend the Company when it unilaterally stopped paying for the defense. The Court expressly stated that Medmarc engaged in "unlawful conduct" by unilaterally terminating the defense. Although the coverage dispute remains pending between the parties, the Court held that "Medmarc will mostly likely lose its claim" seeking to terminate the payment of the defense, and therefore, it must continue to pay the defense until the coverage dispute is resolved. The Court also awarded Biostage its attorneys' fees and costs arising from Medmarc's breach of the duty to defend. The Court's decision states that "when an insured goes to court and shows that the insurer has breached its duty to defend, the insured is entitled to recovery any reasonable attorneys' fees and other litigation expenses that it incurred to do so." Biostage has since discontinued development of the Biostage Tracheal Implant and is now pursuing the development of the Biostage Esophageal Implant to treat adults with severe esophageal disease (including esophageal cancer), and also birth defects in the esophagus in babies.
お知らせ • Jan 12Biostage Announces Publication of Paper Establishing the Basis for Using its Product to Treat Birth Defects in the Esophagus in BabiesBiostage, Inc. announced the publication of paper establishing the basis for using its product to treat birth defects in the esophagus in babies. The piglets gained weight steadily over the course of the study and eventually tripled their size, showing that the regenerated esophagus grows with the patient. The paper states that current techniques for repairing birth defects in the esophagus, "have significant costs, complication rates, lengthy hospital stays, and significant morbidities. Therefore, the development of novel approaches that bridge a primary long gap…are highly desired." Dr. Christine Finck, Surgeon in Chief, Connecticut Children's Medical Center, who performed the surgeries, said "this technology has the potential to provide a novel therapy for some of their must fragile patients." Biostage has previously reported on the first-in-human regeneration of an esophagus in an adult cancer patient, performed at Mayo Clinic and published in JTO Clinical and Research Reports in August 2021. That paper concluded that the Biostage Esophageal Implant would have, "considerable clinical use." The FDA has already approved a 10-patient, phase 1/2 clinical trial for repair of the esophagus in adults. The FDA has indicated a willingness to consider expanding the current clinical trial to include pediatric subjects once the safety of the implant is shown in adults. Hence, they expect the repair of birth defects in the esophagus to be an additional indication for which Biostage will seek FDA approval.
お知らせ • May 18Biostage, Inc. announced delayed 10-Q filingOn 05/17/2021, Biostage, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Biostage, Inc. announced delayed annual 10-K filingOn 03/31/2021, Biostage, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 05Biostage, Inc. Announces Resignation of James Mastridge as Interim Vice President of Finance or Principal Accounting and Financial OfficerOn January 29, 2021, Danforth Advisors, LLC (“Danforth”) notified Biostage, Inc. (the “Company”), that Danforth was terminating its Consulting Agreement with the Company. As a result and effective as of such termination, James Mastridge, is no longer serving as the Company’s interim Vice President of Finance or principal accounting and financial officer. The Company is actively in the process of identifying a qualified candidate to serve as the Company’s principal accounting and financial officer.
お知らせ • Jan 26Biostage, Inc. Appoints Herman Sanchez as an Independent DirectorBiostage, Inc. announced that it appointed Herman Sanchez as an independent director to its Board of Directors. Mr. Sanchez has been working in the life sciences industry for over 20 years in various positions including designing and running randomized trial research, optimizing of clinical administration of health services, and working as a strategic consultant to the life sciences industry. He is currently a Senior Partner helping run Trinity Life Sciences’ strategy consulting business. He joined Trinity over a decade ago and has worked closely with clients to support strategic decision making across the product lifecycle. In his work consulting for pharmaceutical/biotech and medical device companies he has covered several diseases/therapeutic areas including oncology, rare and ultra-rare diseases, cell therapies, cardiovascular, diabetes, alcohol abuse/dependence, neurological, orthopedic, and renal diseases. He has been published in peer-reviewed publications on various topics including renal disease, patient epidemiology, medication adherence, suicidal ideation, minority patient recruiting, alcohol use/abuse and depression/anxiety treatment. Mr. Sanchez, prior to working in the life sciences industry, earned an MBA from the Tuck School of Business at Dartmouth and an AB in Psychology from Harvard University.
お知らせ • Aug 21+ 1 more updateBiostage, Inc. announced that it expects to receive $0.3 million in funding from Dao Capital Group LimitedBiostage, Inc. (OTCPK:BSTG) announced that entered into securities purchase agreement for a private placement of 75,000 common shares at a price if $4 per share for gross proceeds of $300,000 on August 18, 2020. The transaction included participation from Dao Capital Group Limited. No brokerage or finder’s fees or commissions are or will be payable by the company. The securities will be issued pursuant to exemption provided under Regulation D.